PECAM1 and neoplasm: Intratumoral application of artLCMV vectors changed the non-hematopoietic tumor stroma with a significantly increased proportion of PDPN+ FSCs (Fig. 4a), while the fractions of CD31+ blood endothelial cells and PDPN-negative FSCs cells were reduced (Supplementary Fig. 4a–c).